BioSpace News Archive

Elevation Oncology, Inc. today announced that Joseph Ferra , Interim Chief Executive Officer and Chief Financial Officer of Elevation Oncology, will present at SVB Securities Global Biopharma Conference on Wednesday, February 15, 2023 at 4:20 pm ET.

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, February 22 nd at 11:30 a.m. Eastern Time to discuss its fourth quarter and full year 2022 financial results.

REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will present at the SVB Securities Global Biopharma Conference on Thursday, February 16, 2023.

Medical device and technology company Lazurite announced the schedule of upcoming events where it will be exhibiting, presenting, or attending in support of its ArthroFree® wireless camera system for minimally invasive surgery.

Bicycle Therapeutics plc today announced that management will participate in a fireside chat at the SVB Securities Global Biopharma Conference on February 15th, 2023 at 9:20 a.m. ET.

Silence Therapeutics plc, today announced that Craig Tooman, President and Chief Executive Officer of Silence, will present at the virtual SVB Securities Global Biopharma Conference on Wednesday, February 15th at 3:00 p.m. ET.

Adrestia Therapeutics, a leader in synthetic rescue therapies for genetic diseases, today announced it has co-founded a research consortium to find new treatments for ataxia telangiectasia (AT), a fatal, inherited, progressive neurodegenerative disorder that is typically diagnosed in young children.

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today reported results for the year and the quarter ended December 31, 2022.

Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology announced today that a permanent J-code, J1449, has been issued for ROLVEDON (eflapegrastim-xnst) Injection by the U.S. Centers for Medicare & Medicaid Services (CMS) effective as of April 1, 2023.

Bayer today announced the first patients have been enrolled in the initial trials for its OCEANIC clinical trial program, designed to explore the use of asundexian (BAY2433334).